Advertisement

Journal of Endocrinological Investigation

, Volume 28, Issue 7, pp 396–397 | Cite as

Graves’ ophthalmopathy: Search for shared autoantigen(s) continues

  • L. Bartalena
Editorial

References

  1. 1.
    Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000, 21: 168–99.PubMedGoogle Scholar
  2. 2.
    Wiersinga WM, Prummel MF, Terwee CB. Effects of Graves’ ophthalmopathy on quality of life. J Endocrinol Invest 2004, 27: 259–64.PubMedCrossRefGoogle Scholar
  3. 3.
    Bartalena L, Marcocci C, Pinchera A. Graves’ ophthalmopathy: a preventable disease? Eur J Endocrinol 2002, 146: 457–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Bartalena L. Smoking and Graves’ disease. J Endocrinol Invest 2002, 25: 402.PubMedCrossRefGoogle Scholar
  5. 5.
    Hegedus L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves’ ophthalmopathy. J Endocrinol Invest 2004, 27: 265–71.CrossRefGoogle Scholar
  6. 6.
    Bartalena L, Tanda ML, Piantanida E, Lai A, Pinchera A. Relationship between management of hyperthyroidism and course of the ophthalmopathy. J Endocrinol Invest 2004, 27: 288–94.PubMedCrossRefGoogle Scholar
  7. 7.
    Bartalena L, Marcocci C, Bogazzi F, et al. Relationship between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1998, 338: 73–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev 2003, 24: 802–35.PubMedCrossRefGoogle Scholar
  9. 9.
    Ajjan RA, Weetman AP. New understanding of the role of cytokines in the pathogenesis of Graves’ ophthalmopathy. J Endocrinol Invest 2004, 27: 227–45.CrossRefGoogle Scholar
  10. 10.
    Bahn RS. TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves’ ophthalmopathy. J Endocrinol Invest 2004, 27: 216–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Ludgate M, Baker G. Inducing Graves’ ophthalmopathy. J Endocrinol Invest 2004, 27: 211–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 2000, 52: 267–71.CrossRefGoogle Scholar
  13. 13.
    Mikozami T, Salvi M, Wall JR. Eye muscle antibodies in Graves’ ophthalmopathy: pathogenic or secondary epiphenomenon? J Endocrinol Invest 2004, 27: 221–9.Google Scholar
  14. 14.
    Marinò M, Chiovato L, Lisi S, Altea MA, Marcocci C, Pinchera A. Role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy: the hypothesis of Kriss revisited. J Endocrinol Invest 2004, 27: 230–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Lisi S, Botta R, Agretti P, et al. Poorly specific binding of thyroglobulin to orbital fibroblasts from patients with Graves’ ophthalmopathy. J Endocrinol Invest 2005, 28: 420–4.PubMedGoogle Scholar
  16. 16.
    Bartalena L, Wiersinga WM, Pinchera A. Graves’ ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 2004, 27: 295–301.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2005

Authors and Affiliations

  • L. Bartalena
    • 1
  1. 1.Department of Clinical MedicineUniversity of InsubriaVareseItaly

Personalised recommendations